【摘要】 目的观察恩替卡韦联合胸腺肽治疗高病毒载量慢性乙型肝炎(CHB)疗效。方法 112例CHB患者随机分为恩替卡韦组(60例)和恩替卡韦联合胸腺肽组(52例)。恩替卡韦组口服恩替卡韦,联合组加用皮下注射胸腺肽,疗程均为48周。观察治疗24、48周血清ALT、IL-10、HBV-DNA、HBe Ag水平变化及耐药率。结果两组治疗24、48周后ALT、IL-10水平明显低于治疗前(P<0.01)。联合组ALT、IL-10水平及HBV-DNA、HBe Ag阴转率均优于恩替卡韦组(P<0.01或0.05)。两组的耐药率差异无统计学意义(1.7%vs 1.9%,P>0.05)。结论恩替卡韦联合胸腺肽对高病毒载量CHB的疗效优于单用恩替卡韦。更多还原

【Abstract】 Objective To observe the effect of entecavir with thymosin on chronic hepatitis B(CHB) with high viral load. Methods A total of 112 CHB patients were randomly divided into entecavir(n=60) and combined groups(n=52). Entecavir group were treated with oral entecavir, while combined group accepted oral entecavir and subcutaneous injection of thymosin for 48 weeks. Serum levels of alanine transaminase(ALT), IL-10, HBV-DNA and HBe Ag and drug resistance were observed after 24 and 48 weeks. Results Levels of ALT and IL-10 in two groups decreased after 24 and 48 weeks compared with pretreatment(P<0.01). Level of ALT and IL-10, and negative conversion rate of HBV-DNA and HBe Ag were higher in combined group than those in entecavir group(P<0.01 or 0.05). Drug resistance showed no difference between two groups(1.7% vs 1.9%, P>0.05).Conclusion The combined use of entecavir and thymosin is superior to single use of entecavir for CHB with high viral load.更多还原